1Litwin SM, McNaughton-Collins M, Fowler FJ, et al. The NIH Chronic Prostatitis Symptorn Index (NIH-CPSI): development and validation of a new outcomes treasure. Jurol, 1999; 162: 369- 375.
2Nickel JC, Nigro M, Valiquette L, et al. Diagnosis and treatment of prostatitis in Canada. Urology, 1998; 52: 797-802.
3Krieger JN, Nyberg L Jr, Nickel JC. NIH consensus definition and classification of prostatitis[J]. JAMA, 1999, 282(3):236-237.
4Litwin MS, McNaughton-Collins M, Fowler FJ Jr, et al. The National Institutes of Health chronic prostatitis symptom index: development and validation of a new outcome measure. Chronic Prostatitis Collaborative Research Network[J]. J Urol, 1999, 162(2):369-375.
5Nickel JC, Nigro M, Valiquette L, et al. Diagnosis and treatment of prostatitis in Canada[J]. Urology, 1998, 52(5):797-802.
6Clinical Effectiveness Group(UK) . National guideline for the mangemant of prostitis[J]. Sex Transm Infect, 1999, 75(Supp1):S46-S50.
7Nickel JC, Nyberg LM, Hennenfent M. Research guidelines for chronic prostatitis:consensus report from the first National Institutes of Health International Prostatitis Collaborative Network[J]. Urology, 1999, 54(2):229-233.
8Bahk JY, Hyun JS, Lee JY, et al. Concentration of ofloxacin in canine prostate tissue and prostate fluid after intraprostatic injection of biodegradable sustained-releasing microspheres containing ofloxacin[J]. J Urol, 2000, 163(5):1560-1564.
